Audentes Therapeutics (BOLD) Received its Third Buy in a Row

By Ryan Adsit

After Wedbush and Mizuho Securities gave Audentes Therapeutics (NASDAQ: BOLD) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Ritu Baral maintained a Buy rating on Audentes Therapeutics today. The company’s shares closed yesterday at $37.05.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.3% and a 52.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

Currently, the analyst consensus on Audentes Therapeutics is a Moderate Buy with an average price target of $43.14, representing a 16.4% upside. In a report issued on April 26, H.C. Wainwright also maintained a Buy rating on the stock with a $48 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $46.18 and a one-year low of $17.95. Currently, Audentes Therapeutics has an average volume of 551.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.